S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
Log in

NASDAQ:CORTCorcept Therapeutics Stock Price, Forecast & News

$15.35
+0.40 (+2.68 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.52
Now: $15.35
$15.41
50-Day Range
$14.60
MA: $16.37
$18.26
52-Week Range
$9.70
Now: $15.35
$18.52
Volume1.90 million shs
Average Volume1.02 million shs
Market Capitalization$1.76 billion
P/E Ratio17.44
Dividend YieldN/A
Beta1.09
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushing's syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat metastatic ovarian cancer, as well as in Phase I/II clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer; CORT118335 selective cortisol modulator for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Read More
Corcept Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:CORT
CUSIP21835210
Phone650-327-3270

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$306.49 million
Cash Flow$0.87 per share
Book Value$3.25 per share

Profitability

Net Income$94.18 million

Miscellaneous

Employees166
Market Cap$1.76 billion
Next Earnings Date8/4/2020 (Confirmed)
OptionableOptionable
$15.35
+0.40 (+2.68 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CORT News and Ratings via Email

Sign-up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions

How has Corcept Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Corcept Therapeutics' stock was trading at $10.95 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CORT shares have increased by 40.2% and is now trading at $15.35.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Corcept Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Corcept Therapeutics
.

When is Corcept Therapeutics' next earnings date?

Corcept Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020.
View our earnings forecast for Corcept Therapeutics
.

How can I listen to Corcept Therapeutics' earnings call?

Corcept Therapeutics will be holding an earnings conference call on Tuesday, August 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) issued its earnings results on Monday, May, 4th. The biotechnology company reported $0.25 EPS for the quarter, topping analysts' consensus estimates of $0.22 by $0.03. The biotechnology company earned $93.25 million during the quarter, compared to analysts' expectations of $87.01 million. Corcept Therapeutics had a net margin of 31.64% and a return on equity of 30.00%. The business's revenue was up 43.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.20 earnings per share.
View Corcept Therapeutics' earnings history
.

What price target have analysts set for CORT?

3 brokerages have issued 12 month price objectives for Corcept Therapeutics' stock. Their forecasts range from $15.00 to $20.00. On average, they expect Corcept Therapeutics' share price to reach $17.67 in the next twelve months. This suggests a possible upside of 15.1% from the stock's current price.
View analysts' price targets for Corcept Therapeutics
.

Has Corcept Therapeutics been receiving favorable news coverage?

Media stories about CORT stock have trended negative on Monday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Corcept Therapeutics earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.
View the latest news about Corcept Therapeutics
.

Who are some of Corcept Therapeutics' key competitors?

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), CA (CA), Advanced Micro Devices (AMD), Alibaba Group (BABA), BlackRock (BLK), AbbVie (ABBV), Netflix (NFLX), Energy Transfer LP Unit (ET) and Johnson & Johnson (JNJ).

Who are Corcept Therapeutics' key executives?

Corcept Therapeutics' management team includes the following people:
  • Dr. Joseph K. Belanoff, Co-Founder, Pres, CEO & Director (Age 62)
  • Mr. Gary Charles Robb, CFO & Sec. (Age 56)
  • Mr. Sean Maduck, Sr. VP of Commercial (Age 42)
  • Dr. Christopher Shayne James M.D., Director of Investor Relations
  • Dr. Hazel Hunt Ph.D., Sr. VP of Research

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (6.63%), Parallel Advisors LLC (1.23%), MERIAN GLOBAL INVESTORS UK Ltd (0.69%), SG Americas Securities LLC (0.22%), Mackay Shields LLC (0.18%) and Financial Advisory Service Inc. (0.17%). Company insiders that own Corcept Therapeutics stock include Daniel N Swisher Jr, G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Robert S Fishman and Sean Maduck.
View institutional ownership trends for Corcept Therapeutics
.

Which major investors are selling Corcept Therapeutics stock?

CORT stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, UBS Group AG, Trustcore Financial Services LLC, Mackay Shields LLC, Raymond James & Associates, Financial Advisory Service Inc., Valeo Financial Advisors LLC, and Hancock Whitney Corp. Company insiders that have sold Corcept Therapeutics company stock in the last year include Daniel N Swisher Jr, and G Leonard Baker Jr.
View insider buying and selling activity for Corcept Therapeutics
.

Which major investors are buying Corcept Therapeutics stock?

CORT stock was purchased by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Empowered Funds LLC, First Trust Advisors LP, Bridge City Capital LLC, SG Americas Securities LLC, Exchange Traded Concepts LLC, Hussman Strategic Advisors Inc., and Nisa Investment Advisors LLC.
View insider buying and selling activity for Corcept Therapeutics
.

How do I buy shares of Corcept Therapeutics?

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $15.35.

How big of a company is Corcept Therapeutics?

Corcept Therapeutics has a market capitalization of $1.76 billion and generates $306.49 million in revenue each year. The biotechnology company earns $94.18 million in net income (profit) each year or $0.77 on an earnings per share basis. Corcept Therapeutics employs 166 workers across the globe.

What is Corcept Therapeutics' official website?

The official website for Corcept Therapeutics is www.corcept.com.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.